companies / atavistik-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-17 json
| total_raised | 120,000,000120.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Cambridge USA | |
| industry | unknown | |
| stage | series-b+ |
Atavistik Bio develops precision allosteric small molecule therapeutics by identifying hidden binding pockets on drug targets. The company focuses on patients with oncology and rare disease needs where treatment options are limited. Its proprietary AMPS platform combines computational and experimental techniques to unlock cryptic allosteric sites.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-12-01 | series-d+ | 120,000,000120.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series D+, $120.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |